Latest revenue
$193.5M
as of 2026-03-31
Latest net income
$14.5M
as of 2026-03-31
Net margin
7.5%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.11B
- Enterprise value
- $1.11B
- P/E (trailing)
- 17.6×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $50.79
- 52-wk low
- $28.73
- Beta
- —
- Shares out
- 32.4M
5-year trend
What this company does
Item 1. Business Overview Our mission is to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. We have developed, licensed, and acquired a portfolio of meaningfully differentiated products for use in the treatment of attention deficit hyperactivity disorder (“ADHD”) and moderate to severe pain. We commercialize our products, consisting of Jornay PM, Belbuca, Xtampza ER, Nucynta ER and Nucynta IR (collectively the “Nucynta Products”), and Symproic, in the United States. Jornay PM On September 3, 2024, we acquired Ironshore, which had developed and obtained commercial approval to market Jornay PM in the…
AI summary unavailable — showing raw filing excerpt
Generated from COLL's filing dated 2026-02-26
Key risks
Item 1A. Risk Factors Investing in our common stock involves a high degree of risk. Investors should carefully consider the risks described below, as well as all other information included in this Annual Report on Form 10-K, including our financial statements, the notes thereto and the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” If any of the following risks actually occurs, our business, financial condition, operating results, prospects and ability to accomplish our strategic objectives could be materially harmed. As a result, the trading price of our common stock could decline and investors could lose all or part of their…
AI summary unavailable — showing raw filing excerpt
Generated from COLL's filing dated 2026-02-26
Profitability
Gross margin
59.3%
0.7%Operating margin
23.0%
14.5%Net margin
8.1%
26.5%Return on equity
20.8%
31.1%Return on assets
3.8%
8.8%Leverage
Debt / equity
4.49×
28.4%Long-term debt / equity
1.80×
25.3%Debt / assets
81.8%
5.2%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $193.5M | +8.9% | $14.5M | +499.8% | 7.5% |
Q4 2025 2025-12-31 | $205.4M | +12.9% | $17.0M | +35.3% | 8.3% |
Q3 2025 2025-09-30 | $209.4M | +31.4% | $31.5M | +237.5% | 15.0% |
Q2 2025 2025-06-30 | $188.0M | +29.4% | $12.0M | -38.9% | 6.4% |
Q1 2025 2025-03-31 | $177.8M | +22.7% | $2.4M | -91.3% | 1.4% |
Q4 2024 2024-12-31 | $181.9M | — | $12.5M | — | 6.9% |
Q3 2024 2024-09-30 | $159.3M | +16.5% | $9.3M | -42.4% | 5.9% |
Q2 2024 2024-06-30 | $145.3M | +7.2% | $19.6M | +543.7% | 13.5% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on COLL — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$10.5M
Net activity
−$10.5M
Distinct insiders
11
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns COLL
Institutional value
$539.8M
Total shares held
16.9M
Distinct holders
161
-117 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 5.1M | $169.8M | +34.3K (+0.7%) | Added |
| 2 | Invesco Ltd. | 1.6M | $52.6M | +416.9K (+35.5%) | Added |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 1.3M | $44.1M | — | New |
| 4 | PRINCIPAL FINANCIAL GROUP INC | 1.3M | $42.8M | -18.6K (-1.4%) | Trimmed |
| 5 | DIMENSIONAL FUND ADVISORS LP | 833.2K | $27.6M | +2.7K (+0.3%) | Added |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 680.4K | $22.5M | — | New |
| 7 | EMERALD ADVISERS, LLC | 402.8K | $13.3M | -226.6K (-36.0%) | Trimmed |
| 8 | Assenagon Asset Management S.A. | 312.6K | $10.3M | -199.1K (-38.9%) | Trimmed |
| 9 | EMERALD MUTUAL FUND ADVISERS TRUST | 306.1K | $10.1M | -85.6K (-21.9%) | Trimmed |
| 10 | ROYCE & ASSOCIATES LP | 272.8K | $9.0M | +21.6K (+8.6%) | Added |
| 11 | Bank of New York Mellon Corp | 225.7K | $7.5M | -1.4K (-0.6%) | Trimmed |
| 12 | VANGUARD FIDUCIARY TRUST CO | 219.4K | $7.3M | — | New |
| 13 | Hillsdale Investment Management Inc. | 184.6K | $6.1M | -22.0K (-10.6%) | Trimmed |
| 14 | FRANKLIN RESOURCES INC | 174.4K | $5.8M | +136.6K (+361.7%) | Added |
| 15 | PRUDENTIAL FINANCIAL INC | 170.7K | $5.6M | +95.2K (+126.1%) | Added |
| 16 | THIRD AVENUE MANAGEMENT LLC | 155.1K | $5.1M | -48.3K (-23.7%) | Trimmed |
| 17 | Public Sector Pension Investment Board | 141.3K | $4.7M | -5.4K (-3.7%) | Trimmed |
| 18 | SEI INVESTMENTS CO | 130.6K | $4.3M | +85.8K (+191.6%) | Added |
| 19 | BNP PARIBAS FINANCIAL MARKETS | 122.1K | $4.0M | -97.4K (-44.4%) | Trimmed |
| 20 | Ballast Asset Management, LP | 113.2K | $3.7M | +2.8K (+2.5%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once COLL's latest filing finishes processing.